Citations

Clear

23 citation(s) found for "Sill, J".

Imaging Findings of Chronic Coccidioidomycosis Septic Arthritis and Osteomyelitis of the Shoulder Joint
Sams, Amanda L., Sill, Andrew , Wyse, Aaron J., Fox, Michael G. , Wyse, Aaron

Mayo Clinic

Roentgen Ray Review | March 19, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.2214/r3j.25.01092 Get It

Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies
Federico, Aniello , Schmitt-Hoffner, Felix , Fonseca, Adriana , Geisemeyer, Neal, Bruckner, Katharina , Mauermann, Monika, Sill, Martin , Stichel, Damian , Sturm, Dominik , Schüller, Ulrich , Tauziede-Espariat, Arnault, Capper, David, Abdullaev, Zied , Selt, Florian , Williamson, Lane, Miele, Evelina, Snuderl, Matija, Brandner, Sebastian, Lugt, Jasper van der , Bunt, Jens , Kolenova, Alexandra, Wilson, Yelena , Weintraub, Lauren , Spiegl-Kreinecker, Sabine, Aistleitner, Barbara, Zapotocky, Michal, Ramaswamy, Vijay, Korshunov, Andrey, Jones, Barbara C. , Kjaersgaard, Mimi, Kranendonk, Mariëtte E.G. , Haberler, Christine, Packer, R., Jäger, Natalie, Sahm, Prof Felix, Koster, J., Aldape, Kenneth, Hoff, Katja von , Gojo, Johannes , Kool, M., Varlet, Pascale , Capper, David , Selt, Florian , Antonelli, Manila , Brandner, Sebastian , Bunt, Jens , Raghunathan, Aditya , Ramaswamy, Vijay , Haberler, Christine , von Deimling, Andreas , Sahm, Felix , Aldape, Kenneth , Gojo, Johannes , Kool, Marcel , Von Hoff, Katja , Geisemeyer, Neal, Tauziède-Espariat, Arnault , Capper, David , Schrimpf, Daniel , Donson, Andrew M. , Miele, Evelina , Snuderl, Matija , Łastowska, Maria , Kramm, Christof Maria , Kolenová, Alexandra , Raghunathan, Aditya , Hansford, Jordan R. , Spiegl‐Kreinecker, Sabine , Baroni, Lorena , Zápotocký, Michal , Ramaswamy, Vijay , Korshunov, Andrey , Kjærsgaard, Mimi , Haberler, Christine , Deimling, Andreas von , Sahm, Felix , Pfister, Stefan M. , Kool, Marcel

Mayo Clinic

Neuro-Oncology | December 18, 2025 | Volume: 28 | Issue: 4 | Pages: 1005-1019

10.1093/neuonc/noaf283 | PMID 41429568 Get It

Abstract Background Astroblastomas are rare brain tumors predominantly affecting children and young adults, for which molecular subtypes and clinical management remain undefined. Methods We analyzed tumor samples, molecular profiles, and clinical data from 200 patients, classified as “Astroblastoma, MN1-altered” under WHO criteria, using DNA methylation profiling, DNA/RNA profiling/sequencing, and survival analyses. Results DNA methylation analyses identified 3 groups: Group A (n = 143, characterized by MN1::BEND2 fusions, predominantly supratentorial location, with striking female predominance and favorable survival); Group B (n = 37, epigenetically and transcriptionally closely related to Group A, but characterized by EWSR1::BEND2 fusions, with spinal and infratentorial locations and poor prognosis); and Group C (n = 20, epigenetically and transcriptionally distinct, characterized by MN1::CXXC5 fusions, exclusively supratentorially located, with favorable survival). Progression-free and overall survival were significantly shorter in Group B (5-year PFS 14%; 10-year OS 54%) compared to A (5-year PFS 47%; 10-year OS 89%) and C (5-year PFS 75%; 10-year OS 89%). Radiotherapy improved PFS in Group B (hazard ratio 0.25), while no clear benefit was identified for Groups A and C. Conclusions Astroblastoma, MN1-altered, comprises 3 molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including the identification of potential predictive biomarkers like 14q/16q loss, provide a framework for the development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.
Changes in nutritional status and the development of obesity and metabolic syndrome following pediatric heart transplantation
Sill, Jordan , Lukich, S., Alejos, A., Lim, H. , Chau, P., Lowery, Ray , McCormick, Amanda D. , Peng, David M. , Yu, Stella X. , Schumacher, Kurt R. , Lim, Heang M. , Sill, J , McCormick, A , Peng, D M , Schumacher, K R , Yu, S., Lim, Heang M.

Mayo Clinic

Pediatric Transplantation | May 20, 2024 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/petr.14782 | PMID 38767001 Get It

AbstractBackgroundNutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre‐operative nutrition status has been shown to affect post‐operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long‐term in the post‐transplant period.MethodsA single‐center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1‐year, and 3‐year follow‐up post‐transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z‐score, were utilized in secondary analyses.ResultsOf the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3‐year follow‐up. No underweight patients at listing became overweight/obese at follow‐up. Of patients who were overweight/obese at listing, 88% maintained that status at 3‐year follow‐up. Overweight/obese status at listing, 1‐year, and 3‐year post‐transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post‐transplant metabolic syndrome.ConclusionsThe results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Osteochondral Lesions of the Ankle and Foot
Haug, Logan P. , Sill, Andrew , Kile, Todd A. , Fox, Michael G. , Shrestha, Roman , Sill, Andrew P., Shrestha, Roman, Patel, Karan A.

Mayo Clinic

Seminars in Musculoskeletal Radiology | May 25, 2023 | Volume: 27 | Issue: 03 | Pages: 269-282

10.1055/s-0043-1766110 | PMID 37230127 Get It

AbstractOsteochondral lesions (OCLs) in the ankle are more common than OCLs of the foot, but both share a similar imaging appearance. Knowledge of the various imaging modalities, as well as available surgical techniques, is important for radiologists. We discuss radiographs, ultrasonography, computed tomography, single-photon emission computed tomography/computed tomography, and magnetic resonance imaging to evaluate OCLs. In addition, various surgical techniques used to treat OCLs—debridement, retrograde drilling, microfracture, micronized cartilage-augmented microfracture, autografts, and allografts—are described with an emphasis on postoperative appearance following these techniques.
Postoperative Ankle Imaging, 2022
Sill, Andrew , Haug, Logan P. , Kile, Todd A. , Fox, Michael G. , Shrestha, Roman , Sill, Andrew P., Fox, Michael G , Shrestha, Roman, Patel, Karan A.

Mayo Clinic

Seminars in Musculoskeletal Radiology | June 2, 2022 | Volume: 26 | Issue: 03 | Pages: 203-215

10.1055/s-0042-1750841 | PMID 35654090 Get It

Abstract Postoperative ankle imaging requires knowledge of the underlying surgical techniques, the usefulness of various imaging modalities, as well as an appreciation for the desired clinical outcomes. Surgical procedures discussed in this article are tibiotalar fracture fixation, tibiotalar, subtalar, and tibiotalocalcaneal arthrodesis, total ankle arthroplasty, talar osteochondral lesion repair and grafting, lateral ligamentous repair and reconstruction, and peroneal and Achilles tendon repair and reconstruction. Imaging can play a vital role in determining if the expected outcome has been achieved and identifying complications, with particular emphasis placed on the use of radiographs, computed tomography (including weight-bearing), magnetic resonance imaging, and ultrasonography.
Calcific Tendinosis Reduces Diagnostic Performance of Magnetic Resonance Imaging in the Detection of Rotator Cuff Tears
Sill, Andrew P., Zaw, Taryar, Flug, Jonathan A., Hartigan, David E., Kransdorf, Mark J., Brinkman, Joseph, Fox, Michael G., Sill, Andrew , Zaw, Taryar, Flug, Jonathan A., Hartigan, David E., Kransdorf, Mark J., Brinkman, Joseph, Fox, Michael G.

Mayo Clinic

Journal of Computer Assisted Tomography | November 11, 2021 | Volume: 46 | Issue: 2 | Pages: 219-223

10.1097/rct.0000000000001257 | PMID 35297578 Get It

Objective This study aimed to investigate the effect of calcific tendinosis on the diagnosis of rotator cuff tears (RCTs) on magnetic resonance imaging (MRI) and magnetic resonance arthrography (MRA). Materials and Methods Calcific tendinosis was confirmed radiographically. Two musculoskeletal radiologists then retrospectively and independently reviewed the MRI/MRA examinations, with surgery or arthroscopy performed within 90 days of the MRI. Rotator cuffs were categorized as no tear, partial-thickness tear, and full-thickness tear. Partial-thickness tear/full-thickness tear groups were combined for analysis. Results Forty-eight MRI (mean age, 63.4 years; range, 37–83 years; female-to-male ratio, 29:19) and 7 MRA (mean age, 49.2 years; range, 25–60 years; female-to-male ratio, 4:3) patients were included. Reader 1 and reader 2 sensitivity/specificity values for RCTs on MRI were 95%/50% and 89%/30%, and the values on MRA were 100%/67% and 100%/100%, respectively. Overall agreement was present in 87% (48 of 55; κ = 0.55 [95% confidence interval, 0.26–0.85]). Conclusions Magnetic resonance imaging has decreased specificity in diagnosing RCTs when calcific tendinosis is present. Magnetic resonance arthrography performed better in this population and could be considered.
Prenatal Neuroepithelial Tumor
Sill, Andrew , Gonçalves, Luís F. , Cornejo, Patricia

Mayo Clinic

No container title available | March 31, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20214076 Get It

Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results
Geiersbach, Katherine B. , Sill, Daniel R, Rosario, Kristina M Del, Meyer, Reid G., Spears, Grant M. , Yuhas, Jason, Sukov, William R. , Jenkins, Robert B. , Ocal, Idris Tolgay, Mounajjed, Taofic, Chen, Beiyun, Del Rosario, Kristina M, Yuhas, Jason A, Ocal, Idris T, Geiersbach, Katherine

Mayo Clinic

American Journal of Clinical Pathology | March 2, 2021 | Volume: 156 | Issue: 5 | Pages: 886-894

10.1093/ajcp/aqab042 | PMID 33942843 Get It

Abstract Objectives We investigated the impact of our laboratory’s reflex testing process for resolving ERBB2 (HER2) status on breast cancer samples that require additional workup after fluorescence in situ hybridization (FISH), per guideline recommendations published in 2018 by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP). Methods In total, 500 breast cancer specimens with ERBB2 FISH results in groups 2 through 4 (all reported as immunohistochemistry [IHC] equivocal [2+] at external laboratories) were resubmitted for IHC testing in our laboratory. Per the ASCO/CAP guideline, FISH was rescored when internal IHC was also equivocal (2+), targeted to tumor areas demonstrating more intense IHC staining, if observed. Results Reflex IHC/FISH testing changed the final reported ERBB2 status in 185 of 500 (37.0%) samples. Result changes included discordant IHC (n = 4 score 0, n = 132 score 1+, and n = 16 score 3+) and discordant FISH (n = 33). Numerical differences in FISH scores were comparable for targeted vs nontargeted FISH rescoring (P = .086 for ERBB2 copy number; P = .49 for ERBB2 ratio). Two cases showed larger differences in FISH scores, suggesting heterogeneity. Conclusions Retesting of breast cancer samples with equivocal IHC frequently changes IHC results, but targeted reanalysis of borderline FISH results rarely identifies significant differences in ERBB2 copy number or ratio.
HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization
Geiersbach, Katherine B. , Sill, Daniel R, Meyer, Reid G., Yuhas, Jason, Sukov, William R. , Mounajjed, Taofic, Carter, Jodi M. , Jenkins, Robert B. , Chen, Beiyun, Yuhas, Jason A, Carter, Jodi , Geiersbach, Katherine

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 28, 2020 | Volume: 145 | Issue: 7 | Pages: 883-886

10.5858/arpa.2020-0273-oa | PMID 33112955 Get It

Context.— Guidelines for HER2 testing in breast cancer have changed over time, from the US Food and Drug Administration guideline to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines published in 2007, 2013, and 2018. Objective.— To investigate the change in assignment of HER2 status in breast cancers with equivocal (2+) immunohistochemistry (IHC) results by fluorescence in situ hybridization (FISH) following implementation of the ASCO/CAP 2018 guideline. Design.— The study included 3556 invasive breast cancers that were HER2 equivocal (2+) by IHC and were submitted to our FISH laboratory after July 2018. Reflex testing (with repeat IHC staining) was performed on certain categories of FISH results known as groups 2, 3, and 4. Concomitant review of IHC and FISH was performed on these reflex cases per 2018 guideline recommendations. The FISH data were analyzed to compare US Food and Drug Administration and ASCO/CAP 2007, 2013, and 2018 interpretations. Results.— Of 3548 invasive breast cancers with complete data available, the percentage agreement for FISH according to different guidelines was highest for ASCO/CAP 2018 versus US Food and Drug Administration (96.5%), followed by ASCO/CAP 2018 versus 2007 (93.8%), and lowest with ASCO/CAP 2018 versus 2013 (83.7%). Per the 2018 guideline, reflex IHC testing was performed on 633 breast cancers (17.8%); the majority of reflex testing results were negative (541 of 633; 85.5%). The overall distribution of HER2 FISH results (per the 2018 guideline) was 88.5% negative and 11.5% positive. Conclusions.— By eliminating the equivocal FISH category, the 2018 ASCO/CAP guideline significantly reduced the HER2 FISH–positive rate in tumors with equivocal (2+) IHC results.
Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.
Tewari, Krishnansu S. , Sill, Michael W. , Long, Harry J., Reid, Thomas , Michael, Helen E., Monk, Bradley J. , Ramondetta, Lois Michelle , Landrum, Lisa M. , Oaknin, Ana , Leitão, Mario M.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 3-3

10.1200/jco.2013.31.15_suppl.3 Get It

3 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.